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2Résumé
Trois agents chélateurs (l’acide diéthylène triamine penta-acétique, DTPA; l’acide méso-2,3-
dimercaptosuccinique, DMSA; l’acide 2,3-dimercapto-1-propanesulfonique, DMPS) ont été
comparés quant à leur efficacité à mobiliser du cadmium (Cd) accumulé dans le tissu rénal.
Des reins prélevés chez des rats exposés durant 3 j au Cd (acétate de Cd , 0.75 mg/kg·j, i.p)
ont été isolés et perfusés in vitro, à l’aide d’un système de reperfusion utilisant une solution de
Krebs-Henseleit, pH 7.4, contenant 8 acides aminés et 6% d’albumine. Les concentrations de
Cd dans le perfusat et l’urine ont été mesurées par spectrométrie d’absorption atomique. Six
périodes de clearance, après une période d’équilibration de 20 min, ont été obtenues. Le
DMSA et le DMPS ont mobilisé le Cd à partir du tissu rénal, comme l’ont montré les
augmentations dose-dépendantes des concentrations de Cd dans l’urine et le perfusat.
L’accumulation de Cd était nettement plus élevée dans le perfusat que dans l’urine, indiquant
que  l’effet des chélateurs se marquait surtout au niveau tubulaire basolatéral. Le DTPA
n’induisait qu’une faible mobilisation de Cd dans l’urine et le perfusat, et son efficacité était
clairement inférieure à celle des autres chélateurs. Comme prévu, la quantité de Cd présente
dans le tissu rénal après perfusion par le DMSA ou le DMPS diminuait en fonction de
l’efficacité des chélateurs, jusqu’à des valeurs inférieures de 46% au taux rénal de Cd avant
perfusion. Le DMPS apparaissait induire une excretion urinaire de Cd plus importante que
celle induite par le DMSA, une caractéristique  qui pourrait être liée à une sécrétion tubulaire
du chélateur, qui a été décrite antérieurement. Un intervalle de temps prolongé (1-2 semaines)
entre le moment de l’administration du Cd et la perfusion du rein avec le DMPS induisait une
augmentation de l’excrétion urinaire de Cd. Tous les chélateurs se sont montrés
néphrotoxiques à concentrations élevées.
Mots-clés: rein isolé perfusé; DTPA; DMSA; DMPS; Cd; néphrotoxicité; antidotes;
chélateurs.
Abstract
The ability of 3 chelators (diethylene-triamine pentaacetatic  acid: DTPA; meso-2,3-
dimercaptosuccinic acid: DMSA; 2,3-dimercapto-1-propanesulfonic acid: DMPS) to mobilize
cadmium (Cd) accumulated in renal tissue following ip administration of Cd during 3 days
3was evaluated in vitro by the isolated perfused rat kidney technique, using a reperfusion
system with a Krebs-Henseleit solution containing 8 amino acids and 6% albumin. Cd
concentration in urine and perfusate was measured, by atomic absorption spectrophotometry,
in samples collected during three 20-min clearance periods, after a 20 min equilibration time.
DMSA and DMPS mobilized Cd from renal tissue, as shown by dose-dependent increases  of
Cd in urine and perfusate. A much larger amount of Cd  appeared in the perfusate than in
urine, indicating that the chelators were mostly effective by removing Cd from basolateral side
of renal tubules. DTPA elicited a much smaller increase of Cd excretion both in urine and
perfusate and was clearly less effective than the 2 other chelators. As expected, total amount
of Cd in renal tissue after exposure to DMSA or DMPS decreased in relation with the efficacy
of chelators to mobilize Cd, down to 46% of the initial values of tissue Cd content. DMPS
appeared to induce a larger Cd urinary excretion as compared to DMSA, a characteristic
which may be related to a secretory tubular transport of the chelate, as reported previously. A
larger time-interval between Cd administration and perfusion of DMPS was associated with
an enhanced removal of Cd from renal tissue. All chelators showed renal, concentration-
dependent  functional toxicity.
Key words: IPRK; chelators; DTPA; DMSA; DMPS; Cd; nephrotoxicity; Cd antidotes.
Introduction
Exposure to cadmium (Cd) entails acute and/or chronic, dose-related toxicity which is
expressed in a number of target organs (1).  Acute toxicity induced by Cd results, depending
on the exposure conditions, in gastrointestinal or pulmonary lesions. In cases of prolonged
exposure, the metal accumulates mostly in the liver and kidneys: up to 80 % of the body
burden is found in these two organs (2). Renal accumulation of Cd, related to its extremely
4long biologic half-life (ca. 10-20 years) results in a nephropathy which has been described in
occupationally exposed workers as well as in population groups living in a polluted
environment (2). Cd is first accumulated in the liver, where it induces the synthesis of
metallothionein (MT). The Cd-MT complex is then slowly released into the circulation and is
taken up in the kidneys, where the metal induces new synthesis of MT and is stored for
prolonged periods. Renal damage occurs above a threshold level of the toxic metal,  when the
capacity of MT synthesis by unbound Cd in tubular cells is exceeded (3).
In order to develop a possible therapeutic approach in cases of human Cd poisoning, the
ability of  various Cd chelators to mobilize and increase the excretion of the toxic metal has
been investigated experimentally (4). The compounds used for this purpose included in
particular the following: dimercaptopropanol (5,6,7); EDTA and DTPA (8); DMPS (9,10);
DMSA (9,10); dithiocarbamates (5,11-15). The ability of chelating agents to reduce toxic
metal cell content has also been tested in cell cultures previously exposed to Cd (16,17).
While several studies indicated that chelators increased the mobilization and reduced the
kidney levels of Cd, other investigations provided evidence that redistribution of Cd may
occur following chelator administration, resulting in enhanced Cd levels in some tissues,
notably the kidney, and thus suggesting potential deleterious effects of chelators for treating
Cd poisoning (6,13). Such a redistribution appears to occur most notably when the time-
interval between Cd and chelator administration is short (5,6).
The characterization of the specific effect of chelators on renal Cd content  is made difficult
by the metal redistribution mentioned above. The present study was therefore intended to
investigate the comparative short-term effect of several chelators on the renal Cd burden in
conditions where systemic redistribution could be precluded. For that purpose, we resorted to
an isolated, perfused rat  kidney (IPRK) preparation, which has been  described in detail
previously (18,19). Despite the functional limitations of such a preparation, it should allow to
delineate the ability of chelators to mobilize Cd in kidneys from animals previously exposed
to the metal, in the absence of any redistribution. This technique has been used, in relation
with studies on Cd toxicity, to investigate the uptake of the metal in various experimental
conditions (20,21), and to study the kinetics of chelators (22). We planned to evaluate the
comparative efficacy of three chelators to mobilize Cd from kidneys of rats at short (3 days) or
longer (1 or 2 weeks) times after Cd administration to the animals.
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6Methods
Male Wistar rats (Kleintierfarm Madörin, Füllinsdorf, BL, Switzerland) weighing between
350 and 550 g were used. The animals had free access to rat pellets and water, but were fasted
overnight before perfusion. During the three days preceding the perfusion experiments, they
received one i.p. injection per day of cadmium acetate (CdA), 0.75 mg/kg b.w. Twenty-four
hours after the third injection, the right kidney was isolated and perfused.
Kidney preparation
After induction of anesthesia (Na pentobarbital, ca. 60 mg/kg i.p.), heparin (35 IU, Fluka AG,
Buchs) was injected through the jugular vein, and the right ureter was cannulated with PE-50
polyethylene tubing with a short tapered tip. For the experiments with non-filtering kidneys,
the right ureter was ligated during 20-30 min before removal of the kidney.
Isolated kidney perfusion was carried out as described previously (18,19). Briefly, the right
renal artery was cannulated via the superior mesenteric artery, and perfusion was started
immediately. The isolated right kidney was then transferred to the perfusion setup, using a
recirculating system (using 70 ml of perfusion fluid at 37 °C). Perfusion fluid was a Krebs-
Henseleit bicarbonate (KHB) buffer containing (mM): NaCl 116, KCl 3.5, NaHCO3 25,
MgSO4 · 7H2  O  2.44, KH2PO4 1.53, CaCl2· 2H2O  1.5. Bovine serum albumin (Fraction V,
Boehringer Mannheim, Germany) was added at a concentration of 6%. The albumin was
previously dialyzed for 18-24 h against protein-free KHB. The medium contained also glucose
(6.6 mM) and  eight amino-acids (Sigma, St-Louis, USA): methionine 0.5, alanine 2, glycine
2, serine 2, arginine 1, proline 2, isoleucine 1, aspartic acid 3, isoleucine 1 mM. Before the
experiments,  the perfusate was filtered through a 0.22 m filter, was gassed  with  O2/CO2
(95:5) for 20 min, and pH was adjusted to 7.4. The perfusate was prepared fresh for each
experiment. Perfusions were carried out at 37 °C.
Experimental protocol
7Isolated kidney perfusion was carried out in kidneys of either normal or Cd-exposed rats. In
the latter group, Cd was administered (0.75 mg/kg, i.p) during 3 days prior to the perfusion.
The Cd-mobilizing effect of three chelators was studied: calcium trisodium salt of
diethylenetriaminepentaacetic acid (DTPA); meso-2,3-dimercaptosuccinic acid (DMSA); 2,3-
dimercaptopropane sulfonic acid, Na+ salt (DMPS). DTPA was prepared according to
Cantilena et al (8). The following concentrations of chelators were used: DTPA: 7.1 and 14.2
mM (3.6 and 7.2 g/L, respectively); DMPS: 2.4, 11.9 and 23.8 mM (0.5, 2.5 and 5 g/L,
respectively); DMSA: 5.5 and 27.4 mM (1.0 and 5.0 g/L respectively). All chemicals were
from Sigma.
Kidneys from Cd exposed rats were perfused with various concentrations of the chelators (cf
Table 3), 24 hours after the last Cd injection. In additional groups of rats, the effect of DMPS
(11.9 or 23.8 mM) was evaluated after 1 or 2 weeks following the last Cd injection.
Perfusions lasted 80 min. Renal function was measured during 6 consecutive 10-min
clearance periods, beginning 20 min after renal artery cannulation. Samples (1 ml) of
perfusate were collected at the mid-point of each period for clearance estimates. Urine
samples were collected during 10 min, and volume was estimated gravimetrically.
The total amount of Cd was measured in left kidneys, and in right kidneys after perfusion.
Tissues were digested in 2 ml HNO3  65% (Suprapure, Merck) at 110°C during 3 h.
Analyses
Inulin clearance measurements were used to evaluate GFR. The concentration of inulin
(Polyfructosan, Laevosan) in urine and perfusate was measured by spectrocolorimetry, after
acid digestion (23). Na and K were estimated by flame photometry (Beckman, Electrolyte 2).
Glucose was measured by the glucose-oxydase method. Cadmium in acid-digested tissues and
fluids was estimated  by atomic absorption spectrometry, using electrothermal activation, as
reported previously (24)
Calculations
8Cd content in renal tissue was calculated from the wet weights and the concentration in the
ashing solutions.Total Cd urinary excretion was calculated from urine concentrations and
urine volume. Total amount of Cd in the perfusate was calculated from the concentration at
the end of the experiment, and the volume of perfusate.
Statistics
All results are expressed as mean ± standard error of the mean. The statistical significance of
differences was evaluated by the Mann-Whitney, non-parametric test. P<0.05 was considered
as the level of significance.
9Results
IPRK function. In order to validate the IPRK set-up used in the present work, we measured
the main functional properties of the present preparation, using 10 kidneys from normal rats
for 3 clearance periods of 20 min each. Results are presented in Table 1. GFR values remained
stable during the 60 min of clearance studies, while FENa tended to increase until the last
period, but remained between approximately 6 to 10% of filtered load. Glucose reabsorption
was extensive at the three time periods.
Effect of Cd on renal function. In order to evaluate the effect of Cd pretreatement on IPRK
function,  the main functional properties of 10 kidneys from rats pretreated or not with Cd
were compared during 3 clearance periods of 20 min each. As shown in Table 2, renal
functional parameters were little affected by 3 days of Cd administration, with the only
exception of FEK.
Effects of Cd chelators on Cd mobilization. The Cd chelating properties of  the various agents
used in the present study are summarized in Tables 3 to 5.  Cd content of urine and perfusate
was increased, as compared to controls, with all chelators. These effects were first estimated
by  measuring the total amount of Cd remaining in the renal tissue after perfusion, which was
compared to the initial tissue concentration as measured in the left, unperfused kidney. The
effect of various chelators is indicated in Table 3. It appears that DMPS  and DMSA induced a
clear-cut, dose related effect on Cd tissue content, while DTPA remained  ineffective (Table
3). Table 4 summarizes the changes in urinary and perfusate Cd content during perfusion with
chelators. The results are expressed as percentages of initial Cd concentrations in renal tissue.
It appears that both perfusate and urinary Cd content increased in a dose-related manner with
DMPS or DMSA perfusion, but not with DTPA. The highest mobilizing effect (urine +
perfusate) of the chelators reached 15.7% (DMPS) and 18.5% (DMSA) of the initial amount
of Cd in the renal tissue. The urinary contribution (Table 4, 4th column) decreased with
increasing concentrations of chelators. The concentration-related effects of DMPS and DMSA
on Cd mobilization into urine or perfusate are represented in Fig. 1. The effects of the larger
dose of the three chelators on urinary cumulative Cd excretion are presented in Fig. 2,
showing the higher efficacy of DMPS.
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Effects of DMPS at longer time intervals after Cd administration. The efficacy of DMPS at
two doses to mobilize renal Cd was evaluated after 1 or 2 weeks following the last Cd
injection. As shown in Table 5, the total amount of Cd released into urine and perfusate was
higher following a delayed administration of DMPS, as compared to an early (24 h)
administration. This increase, which occurred in the perfusate but not in urine, reached
statistical significance at lower concentration of DMPS, at 1 and 2 week intervals. Average Cd
content in renal tissue was higher after 1 and 2 weeks than 24 h following Cd injection.
Effects of chelators on overall renal function. As shown in Table 6, GFR decreased with
increasing concentrations of DMPS. Similar changes occurred with the two other chelators,
GFR decreasing from 0.42 (controls) to 0.26 ml/min with Ca-Na3 DTPA (14.2 mM), and to
0.12 ml/min with DMSA (27.4 mM). Corresponding  increases of fractional Na reabsorption
were observed.
Non-filtering kidneys. The effects of DMPS (11.9 mM) upon Cd levels in perfusate were
evaluated in 5 non-filtering kidneys (ureter ligated 30 min before, and during perfusion). The
amount of Cd recovered at the end of the experiment in the perfusate of non-filtering kidneys
(2.7   0.7%), expressed as percentage of the initial amount of Cd in renal tissue, did not
differ significantly from that measured in filtering kidneys (3.3    0.8%).
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Discussion
The present study aimed at evaluating the efficacy of three chelators on mobilizing Cd
accumulated in the kidneys of rats previously exposed to the toxic metal. In order to prevent a
possible redistribution of metal from other organs, and to avoid systemic effects resulting
from exposure to chelators, we resorted to an isolated perfused rat kidney preparation. The
system used was similar to that pioneered by Bowman (19) and described by Maack (18). The
functional properties of our preparation, as reported in Table 1, appeared appropriate to carry
out the present study. Thus, GFR, Na+, K+ and glucose excretion were in the range of those
measured previously by other authors using IPRK preparations (18-21). The arterial perfusion
pressure was kept in the low range (75-80 mm Hg) in order to maintain a fractional
reabsorption of Na+ between  90-95%. Functional parameters showed a relative stability
during the three 20-min experimental periods, and were little affected by previous
administration of Cd (Table 2).
Addition of chelators to the perfusate induced clear-cut changes in Cd handling by the
perfused kidney. All compounds elicited an increase of Cd content either in the perfusate, the
urine or both. These effects were concentration-dependent for DMPS and DMSA, whereas
they were not for DTPA. Furthermore, the latter compound remained clearly much less
effective than the two other chelators, as shown by the much smaller changes in perfusate and
urine Cd content, and the absence of measurable decrease of Cd  in  perfused kidneys (Table
3). In contrast, both DMPS and DMSA elicited a large increase of Cd in perfusate, and a
smaller rise in urine Cd content.
It is worth noting  that Cd was mobilized from renal tissue by DMSA and DMPS to a much
larger extent into the venous effluent  than into urine, a discrepancy which even increased at
larger chelator concentrations (Table 4). These findings would suggest that the effective
chelating agents act mostly at the basolateral tubular side. Urinary Cd might result from Cd-
chelator complexes ultrafiltered after chelation and recirculation, or from Cd directly
mobilized at the luminal side by ultrafiltered free chelator compounds. Our findings favor the
first hypothesis, most notably based on the observation that changes of Cd content in perfused
kidneys with tied ureters did not differ from those of filtering kidneys. Since ureter ligation in
IPRK has been shown to drastically reduce GFR to non measurable values (20), it appears that
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reduction of renal tissue Cd induced by chelators results mostly from effects at the basolateral
level.
It is well known that in chronic exposure renal Cd is mostly bound to intracellular
metallothionein. Since metallothionein-bound Cd might be less available to chelating agents,
we investigated the effects of increasing the time interval between Cd administration and
exposure to a chelating agent. We assumed that essentially all renal Cd, at one or two weeks
after the last Cd injection, would be bound to metallothionien. We used DMPS as a chelating
agent, since it appeared the most effective in the previous experiments. As shown in Table 5, a
longer delay increased rather than reduced the chelating effects of DMPS, as shown by the
much larger Cd content in the venous effluent. We have no definitive explanation for these
findings, though one could consider the hypothesis that the toxic effects of Cd in renal tubular
cells were more widespread 1 or 2 weeks after Cd administration, resulting in an enhanced
permeability  of basolateral cell membranes to the chelator and an apparent increased
chelating efficacy.
Though the overall chelating efficacy of DMPS and DMSA were similar in our experimental
conditions, it appeared that DMPS enhanced the urinary excretion of Cd to at larger extent
than DMSA when cumulated amounts of urinary excretion of Cd were considered (Fig. 2).
Though, as discussed above, the urinary contribution to the mobilization of Cd remains small,
DMPS might show distinct characteristics with respect to its tubular handling. Thus,
Klotzbach et al (23) have shown, in IPRK studies, that net tubular secretion of DMPS occurs,
indicating a carrier mediated transport process of the organic anion type, since the transport
was inhibited by probenecid and para-aminohippurate. This secretory pathway may contribute
to the efficacy of DMPS as a chelating agent for toxic metals accumulated in the kidney.
Though our experiments were not designed at investigating the tubular transport
characteristics of the chelators, they suggest that DMSA and DMPS differ in their ability to
increase urinary Cd excretion, a property which may be related to the tubular kinetics of
DMPS.
As mentioned previously, the fraction of mobilized Cd excreted into urine decreased with
increasing doses of chelators. This observation may be related to the toxic effects of high
concentrations of chelating compounds on renal function. Thus, as illustrated in Table 6,
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marked decreases of GFR and other renal functions occurred at high concentrations of DMPS,
and would be expected to reduce the excreted amount of chelated Cd. Similar conclusions
applied to DMSA and DTPA as well.
In conclusion, our studies with the IPRK preparation point to a higher efficacy of DMPS and
DMSA than of DTPA at mobilizing Cd from renal tissue. This observation is consonant with
the known kinetic properties of these chelators,  the distribution of DTPA  being restricted to
the extracellular space whereas the two other chelators are known to be able to cross the cell
membrane. Cd mobilization from renal tubular cells proceeds mostly at the basolateral side,
ultrafiltration and urinary excretion of the Cd-chelate occurring subsequently, and following
systemic distribution in whole animals experiments. Specific transepithelial secretory
transport of  DMPS may further enhance the urinary excretion of the chelator and bound Cd.
All chelators used in the present study showed functional renal toxicity at high concentrations.
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Table 1. Functional data of isolated kidneys from normal rats during 60 min perfusion.
__________________________________________________________________________
Time (min)
0-20 20-40   40-60
__________________________________________________________________________
Renal artery pressure (mm Hg)       76.1    1.5       75.7   1.4       78.6    1.4
Kidney perfusion rate (ml/min)       31.7    0.6       35.7   0.4       38.0    0.4
GFR (ml/min)       0.43    0.03     0.53    0.03    0.49    0.04
Urine flow (l/min)       39.7    4.2       66.2    5.9      66.3    6.0
Fractional excretion (%):
Na+        6.3    0.8          8.8    1.2        9.8    1.2
K+      55.0    2.3        68.3    3.1      63.2    3.0
Fractional reabsorption glucose (%)       97.5    0.1        97.1    0.2      95.5    0.4
__________________________________________________________________________
(mean    SEM; n=10 rats)
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Table 2. Functional data of  isolated perfused kidneys from untreated rats or rats injected with
Cd (3 x 0.75 mg/kg Cd acetate)
__________________________________________________________________________
Control Cadmium
__________________________________________________________________________
Renal artery pressure (mm Hg) 76.8    1.4 70.5    0.8
Kidney perfusion rate (ml/min) 35.1    0.6 33.4    0.5
GFR (ml/min) 0.48    0.03 0.42    0.03
Urine flow (l/min)    57.4    7.6 53.2    6.3
Fractional excretion (%):
Na+   8.3    1.0   8.4    1.3
K+ 62.2    2.9 38.2    2.1*
Fractional reabsorption glucose (%) 96.7    0.3 95.8    0.4
__________________________________________________________________________
(mean    SEM; n=10 rats in each group)
*: significantly different from controls (p < 0.05)
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Table 3. Cd content of the right and the left (unperfused) kidneys.
__________________________________________________________________________
Cadmium content (g/kidney) Change (%)
    Left       Right
__________________________________________________________________________
Control 48.5    5.0          47.8    4.8 1.1  2.9
DTPA (7.1 mM) 50.6    8.8          46.0    8.1 8.5  3.7
DTPA (14.2 mM) 38.1    4.2          42.2    5.0         -10.5  2.4
DMPS (2.4 mM) 59.0    7.6          53.0    7.2          10.1  2.9 
DMPS (11.9 mM) 50.4    9.1          43.3    8.3          13.3  4.8
DMPS (23.8 mM) 48.4    6.3          26.3    4.2          45.9  6.2
DMSA (5.5 mM) 38.9    7.9          33.8    7.0            9.4  8.3
DMSA (27.4 mM) 36.2    8.5          23.4    6.1          34.8  6.8
__________________________________________________________________________
Cd (g/kidney) measured in whole organs, after perfusion (24 h after the last Cd injection)
of the right kidney (mean    SEM; n= 6 rats in control, 5 rats in experimental groups).
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Table 4. Effects of CaNa3-DTPA, DMPS and DMSA on Cd content in urine and perfusate.
__________________________________________________________________________
U/L (%)     P/L (%)     U+P/L (%)            U/U+P (%)
__________________________________________________________________________
Control        0.06  0.01          0.57  0.22       0.62  0.22 16.21  6.31
DTPA (7 mM)       0.26  0.06**      0.75  0.30       1.03  0.38               31.17  3.86
DTPA (14.2 mM)  0.22  0.06*        0.61  0.32    0.83  0.32              38.22 12.09
DMPS (2.4 mM)    0.34  0.19         0.60   0.12       0.94  0.30              28.08   7.94
DMPS (11.9 mM)  0.67  0.28**     3.30   0.80*     3.97  0.93*            17.72   4.74
DMPS (23.8 mM)  2.84  0.87**    12.88  4.65**  15.72  5.14**          18.47  4.77
DMSA (5.5 mM)   0.25  0.10**       0.61  0.24       0.86  0.34              29.44  2.19
DMSA (27.4 mM) 0.86  0.25**     17.60  5.81**  18.47  5.96**            5.76  1.06
__________________________________________________________________________
(mean  SEM; n=6 rats in control, 6 rats in experimental groups).
U/L, P/L = urinary, resp. perfusate Cd content, as percentage of left kidney tissue (L) Cd
content. U+P = sum of urinary and perfusate Cd content.
*,**: significantly different from control (P<0.05, P<0.005).
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Table 5. Effect of delayed administration of DMPS on Cd content in urine and perfusate.
_____________________________________________________________________________________
         Cd content (g)
          L. K.          R.K.          U/L(%) P/L(%) U+P/L(%)       U/U+P(%)
_____________________________________________________________________________________
DMPS (11.9 mM):
24 h.       50.49.1   44.99.6     0.70.3           3.30.8               3.90.9            17.74.7
1 week                      54.45.8   45.02.1        1.70.5         11.63.6*            13.34.0*          14.65.3
2 weeks                     69.45.2   64.78.1        1.20.3        16.43.8*            17.63.7*             8.42.7
DMPS (23.8 mM)
24 h.                        48.46.2    27.64.6       2.80.9        12.94.7              15.75.1             18.54.8
1 week                     59.95.8    28.31.6       1.10.2        28.96.6              29.96.7               4.20.8
2 weeks                    51.04.5    32.22.9       1.70.2        22.33.9              24.03.9               7.81.5
_____________________________________________________________________________________
(mean  SEM; n = 5 rats in each group)
All values expressed in %. Abbreviations as in Table 4.
*: significantly different from the 24 h. group (p<0.05).
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Table 6. Functional data of isolated kidneys perfused at different DMPS concentrations.
_____________________________________________________________________________________
DMPS:            0 (control)     2.4 mM   11.9 mM   23.8 mM
_____________________________________________________________________________________
Renal artery pressure (mm Hg) 70.50.8       71.21.4    90.61.6    93.32.9
Kidney perfusion rate (ml/min) 33.40.5      38.61.0    29.00.6    26.60.6
GFR (ml/min) 0.420.03     0.310.04   0.300.03  0.200.02
Na+  fractional excretion  (%)    8.41.3       5.41.7     19.24.9    50.22.8
Fract. reabsorption glucose (%)       95.80.4      96.80.4     91.00.9    55.30.2
_____________________________________________________________________________________
(mean  SEM; n = 10 rats in control, 5 rats in experimental groups)
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Legends to Figures.
Fig. 1. Cumulative amount of Cd (g)  excreted in urine (U) or perfusate (P)
after 60 min of DMPS or DMSA perfusion in isolated rat kidneys, 24 hours
after the last Cd injection. N=5 rats.
Fig. 2. Cumulative urinary excretion of Cd (ng) during 6 consecutive 10 min
periods, in isolated rat kidneys, 24 hours after the last Cd injection. N=5 rats (6
controls). Data from the highest concentration of chelators.
